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Abstract
Background Several multi-attribute utility instruments (MAUIs) are available from which utilities can be derived for use in 
cost-utility analysis (CUA). This study provides a review of recommendations from national health technology assessment 
(HTA) agencies regarding the choice of MAUIs.
Methods A list was compiled of HTA agencies that provide or refer to published official pharmacoeconomic (PE) guidelines 
for pricing, reimbursement or market access. The guidelines were reviewed for recommendations on the indirect calculation 
of utilities and categorized as: a preference for a specific MAUI; providing no MAUI preference, but providing examples of 
suitable MAUIs and/or recommending the use of national value sets; and recommending CUA, but not providing examples 
of MAUIs.
Results Thirty-four PE guidelines were included for review. MAUIs named for use in CUA: EQ-5D (n = 29 guidelines), the 
SF-6D (n = 11), HUI (n = 10), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). EQ-5D was a preferred MAUI in 15 guidelines. 
Alongside the EQ-5D, the HUI was a preferred MAUI in one guideline, with DALY disability weights mentioned in another. 
Fourteen guidelines expressed no preference for a specific MAUI, but provided examples: EQ-5D (n = 14), SF-6D (n = 11), 
HUI (n = 9), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). Of those that did not specify a particular MAUI, 12 preferred 
calculating utilities using national preference weights.
Conclusions The EQ-5D, HUI, and SF-6D were the three MAUIs most frequently mentioned in guidelines. The most com-
monly cited MAUI (in 85% of PE guidelines) was EQ-5D, either as a preferred MAUI or as an example of a suitable MAUI 
for use in CUA in HTA.
Keywords Health technology assessment · Cost-utility analysis · Multi-attribute utility instruments · Pharmacoeconomics · 
Guidelines · Utility
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Introduction
Several methods of economic evaluation are utilized in 
health technology assessment (HTA), including cost-utility 
analysis (CUA), a form of cost-effectiveness analysis that 
assesses the value of interventions, typically according to 
the incremental cost per quality-adjusted life-year (QALY). 
A patient’s health state preferences may be measured 
directly to derive utilities, using methods such as standard 
gamble (SG) or time trade-off (TTO). Utilities may also 
be determined indirectly by means of generic or disease-
specific preference-based questionnaires, with responses 
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mapped onto a utility scale using an algorithm that attaches 
weights—generally derived from societal preferences for 
health states. Generic multi-attribute utility instruments 
(MAUIs) are commonly used for the indirect measure-
ment of utilities. Several MAUIs are available for indirect 
measurement of utilities in CUA, including the EQ-5D (two 
versions: EQ-5D-3L and EQ-5D-5L) [1], the Short-Form 
6-Dimension (SF-6D) [2], the Health Utilities Index (two 
versions: HUI2 and HUI3) [3], Assessment of Quality of 
Life (several versions, e.g. AQoL 6D and 8D) [4], 15D [5], 
VR-6D [6] and the Quality of Well-Being (QWB) instru-
ment [7]. Each MAUI has its own descriptive health clas-
sification system and  preference-based algorithm used to 
derive utility scores [8].
Official pharmacoeconomic (PE) guidelines inform 
manufacturers and others on which methods to follow with 
respect to CUA to support applications for access, reim-
bursement, or pricing. Understanding these recommended 
methods is important to facilitate planning for studies and 
gain a better appreciation of the needs of decision-makers. 
There is no international consensus about the content of 
PE guidelines, so recommendations differ among countries 
around the world [9].
As such, the objective of this review was to identify rec-
ommendations from official national PE guidelines about the 
use of MAUIs within CUA; in addition, the review sought to 
understand in which countries national preference weights 
(value sets) were required for the determination of utilities 
using a MAUI.
Methods
HTA agency and PE guideline search
The initial step in the review process involved the identifi-
cation of national HTA agencies worldwide. The following 
databases were reviewed: the National Institute for Health 
Research (NIHR) HTA database; the International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR) 
PE guidelines; the International Network of Agencies for 
Health Technology Assessment (INAHTA); the World 
Health Organization; the European Network for HTA 
(EuNetHTA); HTAsiaLink; and Health Technology Assess-
ment International.
Once HTA agencies had been identified, their webpages 
were reviewed to determine whether they utilized publicly 
available PE guidelines (or outlined PE guidelines within 
their submission guidance documents). This assessment 
was further informed by searches on PubMed and Google, 
as well as the ISPOR PE guidelines database. Where these 
searches suggested relevant official PE guidelines were 
available, but these remained elusive, help was sought to 
obtain them from local health economic experts.
Identification of CUA MAUI requirement 
or recommendation
PE guidelines were included for countries where HTA 
is used to inform the decision-making process for pric-
ing, reimbursement or market access for medicines by the 
national healthcare decision-making body. This definition 
is similar to the one used by ISPOR in their PE guidelines 
database (https ://tools .ispor .org/pegui delin es/). Multina-
tional guidelines (e.g. Mercosur) and subnational guidelines 
(e.g. Catalonia) were excluded.
Once the latest versions of these guidelines were identi-
fied, they were reviewed to determine whether they recom-
mended the use of CUA as a method for economic evalu-
ation. If CUA is recommended, the PE guidelines were 
then reviewed to determine whether specific MAUIs were 
preferred; and if none were preferred, whether examples 
of MAUIs were provided and whether the use of national 
preference weights (value sets) were recommended. When 
clarification was required regarding the status or content 
of PE guidelines or help was needed with the translation 
of relevant guideline sections, input was sought from local 
health economic experts. The focus of this review was only 
on indirect methods for deriving utilities within CUA. This 
method generally involves applying utility algorithms to 
generic or disease-specific preference-based questionnaires; 
guidelines relating to non-MAUI methods such as mapping 
were excluded. The focus of the review was on pharmaceuti-
cal guidelines. Any guidelines relating specifically to medi-
cal devices or technology were considered outside scope. 
The searches to inform this review were undertaken between 
January and March 2019, with additional research and expert 
input gathered until August 2019.
Results
Guideline selection
Documentation from 46 countries was reviewed and 12 
were excluded in line with eligibility criteria, as presented 
in Fig. 1 (Argentina, Austria, Baltic States, Germany, Italy, 
Kazakhstan, Romania, Spain, Switzerland, Tunisia, United 
States, and Uruguay; reasons for the exclusion provided in 
Table 1), leaving 34 official guidelines, which are summa-
rized in this report. The 34 included guidelines were catego-
rized as those that preferred or encouraged the use of a speci-
fied MAUI (Table 2) and guidelines that recommended CUA 
but recorded no preference for a specific MAUI (Table 3).
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MAUI instruments mentioned in official PE 
guidelines
In the 34 guidelines included in the review, the following 
MAUIs were named for use in CUA: EQ-5D (cited in n = 29 
guidelines), the SF-6D (n = 11 guidelines), HUI (n = 10), 
QWB (n = 3), AQoL (n = 2), and Child Health Utility 9D 
index (CHU9D) (n = 1) (Fig. 2). Although not MAUIs, for 
completeness, it should be noted that both the Short-Form 
36-Item Health Survey (SF-36) (n = 1) and use of the disa-
bility-adjusted life-year (DALY) (n = 1) were also grouped 
with MAUIs in two of the guidelines (from Iran and Chile, 
respectively).
Official PE guidelines preferring/encouraging use 
of a specific MAUI
A number of official PE guidelines (n = 15) recommended 
the use of a specific MAUI; these are listed in Table 2. Only 
one instrument, the EQ-5D, was included as a preferred 
MAUI in all 15 guidelines. It was the only preferred MAUI 
in 13 of these guidelines, and in a further two it was pre-
ferred  along with a second instrument (Table 2; Fig. 2). 
Most of these guidelines did not provide a preference for 
which EQ-5D version to use. Six recommended using the 
EQ-5D-3L. The EQ-5D-5L, which has only been available 
for a few years, is recommended as an alternative to the 
EQ-5D-3L in four and preferred in two guidelines (The 
Netherlands and Portugal) (Table 2). In one of the two 
guidelines where EQ-5D or another instrument were cited 
as preferred, the other utility instrument was the HUI (n = 1, 
France) (Table 2). In the Chilean guidelines, DALYs were 
cited as being an alternative to the EQ-5D; however, disabil-
ity weights are different from utilities and not derived using 
a MAUI. This observation is included in the results (Table 2) 
for completeness. None of the identified guidelines preferred 
a MAUI other than the EQ-5D, without also recommending 
the EQ-5D.
Official PE guidelines with no preference 
for a specific MAUI but including named examples
Of the official PE guidelines identified in the search, 14 
expressed no preference for a specific MAUI but did provide 
examples of acceptable instruments within their recommen-
dations (Table 3). A range of examples was provided, with 
the EQ-5D being the most frequently cited MAUI (cited in 
all 14 guidelines, three of which cited the new EQ-5D-5L). 
The next most common MAUI examples were the SF-6D 
and HUI in 11 and nine guidelines, respectively; the QWB 
in three guidelines, the AQoL in two guidelines; and the 
CHU9D in one guideline (Table 3). In the Iranian guidelines, 
there is a reference to the SF-36, but this is not a MAUI and 
our assumption is that they will accept a mapping from the 
SF-36 to the SF-6D.
Fig. 1  Flow chart for inclusion 
of PE guidelines in the review. 
CUA cost-utility analysis, HTA 
health technology assessment, 
MAUI multi-attribute utility 
instrument, PE pharmacoeco-
nomic
Countries where documentation reviewed, 
n=46
Excluded, n=12 
• HTA not required for pricing,
reimbursement  or market access, n=6
• No official published HTA 
guidelines, n=4
• CUA not required in HTA, n=3
• Subnational guidelines only, n=1
• Multinational guidelines, n=2
Official PE guidelines included, n=34
PE guidelines 
recommending or 
requiring use of a specific 
MAUI, n=15
PE guideline with no 
preference for specific 
MAUI but examples 
provided, n=14
PE guideline 
recommending CUA but 
no MAUI examples 
provided, n=5
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Official PE guidelines that recommend the use 
of national preference weights to calculate utilities
Of the guidelines that did not state a preference for a specific 
MAUI (Table 3), most (n = 12) recommended that calcula-
tion of utility weights should be based on preferences from 
the domestic population.
Official PE guidelines that recommend CUA 
but do not provide MAUI examples
Five guidelines were identified that did recommend eco-
nomic evaluation by CUA but did not provide any examples 
of acceptable MAUIs (Table 3). These included guidelines 
issued in Cuba, Finland, Israel, Mexico, and Slovenia.
Discussion
The objective of this review was to provide an overview of 
recommendations from HTA agencies on the use of MAUIs 
in CUA. As far as we are aware, this is the first published 
review to comprehensively summarize the contents of HTA 
guidelines relating to the use of MAUIs in CUA around 
the world. Previous reviews, such as the 2017 study by 
Rowen and colleagues [9], have also explored this topic but 
restricted themselves to specific countries/regions (Australia, 
Canada, Catalonia, England and Wales, France, Germany, 
The Netherlands, Scotland, Sweden). In a 2016 review of 
the use of EQ-5D in Central and Eastern Europe, Rencz 
and colleagues [12] noted the countries where EQ-5D is 
recommended in HTA guidelines. Others have taken a much 
broader approach in their summaries of HTA guidelines and 
only briefly consider recommendations on MAUIs [13].
Six MAUIs were recommended or cited in guidelines; 
EQ-5D, HUI, and SF-6D were the most frequently men-
tioned, with EQ-5D found to be the most dominant meas-
ure. Of the 34 sets of guidelines from around the world that 
were identified in the review, EQ-5D was mentioned in 
85% (n = 29) as a preferred instrument for the determina-
tion of health utilities or as an example of a suitable instru-
ment. Whenever a guideline-recommended specific MAUIs 
(n = 15 guidelines), EQ-5D was found to be the only pre-
ferred instrument in 13 guidelines and one of two preferred 
instruments, along with another MAUI or the DALY, in the 
remaining two guidelines. No other MAUI came close to 
this level of prominence. Reasons provided in some of the 
PE guidelines for preferring a particular MAUI include that 
EQ-5D is a commonly used instrument enabling consistency 
and comparability between data sets, and that a national 
value set is available (Table 2).
The dominance of EQ-5D as a MAUI used in clinical 
studies mirrors the preferences provided in the PE guide-
lines. A review of articles listed on the Web of Science 
between 2005 and 2010 identified 1663 studies that had 
included a MAUI [14]. Of these, 63% used EQ-5D; 15% the 
HUI2 or HUI3; 9% the SF-6D; and the remaining 15% used 
the 15D, QWB, or AQoL.
Table 1  Countries excluded from the review
CUA cost-utility analysis, HTA health technology assessment, PE pharmacoeconomic
a 2002 Baltic Guideline for Economic Evaluation of Pharmaceuticals
b 2015 MERCOSUR (The Southern Common Market) guidelines usually followed
Reason for exclusion
National PE HTA not required for pricing, 
reimbursement or market access decision-
making
No “official” published 
national PE HTA guidelines
CUA not 
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Most of the guidelines referred to EQ-5D in general or 
to the EQ-5D-3L version. Some of these PE guidelines are 
several years old, and therefore the number citing the EQ-
5D-5L—developed to increase sensitivity (discriminatory 
power) while maintaining ease of use [15]—remains rela-
tively low.
Of the 19 PE guidelines that recommend CUA, but pro-
vide no preference for a specific MAUI, 12 included a pref-
erence for MAUIs utilizing national value sets. The use of 
some MAUIs could, therefore, be limited in PE analysis in 
these countries, since preference weights in the national gen-
eral population may not be available.
It is interesting to note that official PE guidelines were 
available from only 34 countries that specified the use 
of QALYs for use in CUA within economic evaluations. 
Although this may in part reflect policy decisions by a 
few governments to use different methods to assess the 
value of medications (e.g. in Germany), in other countries 
the lack of detailed published guidelines is more likely to 
reflect the current more nascent state of their HTA systems. 
However, as resources available for public healthcare con-
tinue to be stretched around the globe, it will be increas-
ingly important for policymakers to be supported with the 
best available evidence on new and existing medications to 
make informed choices with respect to resource allocation 
[16]. Consequently, the HTA environment will continue to 
develop, most notably as countries that did not previously 
have systems in place (e.g. in parts of Eastern Europe, Latin 
America, and Asia) begin to develop and implement them 
[17–20]. As these HTA systems evolve, more official PE 
guidelines will be developed and the number recommending 
the use of indirect methods for deriving utilities within CUA 
can be expected to grow accordingly.
Guidelines relating specifically to medical devices or 
technology were considered outside the scope of this review. 
However, as in the present study, a recently published review 
of European HTA guidelines for medical devices also found 
that EQ-5D was the most frequently mentioned MAUI and it 
was the preferred measure in most national HTA guidelines 
[21].
While the current review provides some interesting 
insights into recommendations on MAUI use in official PE 
guidelines, the findings must be interpreted within the limi-
tations of the study. Although a wide range of sources was 
reviewed, and references cross-checked, some guidelines 
may have been overlooked. Likewise, some of the guide-
lines were not available in English, Dutch, or German, 
necessitating online translation. Although such transla-
tions were validated by local experts, there is always a risk 
that some ambiguity remains. In some cases, it was also 
unclear which guideline from a particular country should 
be used and included in the review; and it may be that even 
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not published or publicly available and would not have been 
identified by the current searches. A further limitation of 
the review is that supplemental informal guidance may be 
provided by HTA authorities in addition to that published 
in official guidelines.
Finally, it is important to recognize that the HTA envi-
ronment is continually evolving and an overview of the sort 
provided here can quickly become outdated. For example, 
several countries (e.g. Argentina) are considering developing 
new HTA structures, and existing PE guidelines will also 
be refined as the science of economic evaluation evolves. 
Regular updating of the review is, therefore, required.
Conclusions
Published official PE guidelines from around the world were 
identified in the current review. There appears to be sub-
stantial consensus among them in terms of choice of MAUI 
instruments, and three instruments (EQ-5D, HUI, SF-6D) 
are each cited in at least 10 country guidelines. By far the 
most common was the EQ-5D, which was cited in 85% of PE 
guidelines either as the preferred MAUI or as an example of 
a suitable MAUI for use in CUA in HTA economic evalua-
tions. The preference for EQ-5D in guidelines was variously 
described as being due to its widespread use in studies, ena-
bling consistency and comparability, and the availability of 
national value sets. Where PE guidelines provided examples 
of MAUIs but did not give a preference, a majority explicitly 
recommended the use of national value sets for the determi-
nation of utilities.
This review provides an overview of the global picture on 
preferences for the use of the MAUIs in official PE guide-
lines. It also provides insight for stakeholders seeking to 
understand what instruments are used in HTA across differ-
ent countries, and for those developing HTA systems and PE 
guidelines in countries that have not previously been part of 
the landscape.
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Fig. 2  MAUIs preferred or provided as an example across identified 
official PE guidelines. AQoL Assessment of Quality of Life, CHU9D 
Child Health Utility 9D, HUI Health Utility Index, MAUI multi-
attribute utility instrument, QWB quality of well-being, SF-6D Short-
Form 6-Dimension. Numbers sum to more than 34 because some 
guidelines cite more than one MAUI
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